Standard BioTools Sells SomaLogic, Pivots with $550M M&A War Chest

BOSTON, Mass. – January 30, 2026 – Standard BioTools Inc. today finalized the sale of its SomaLogic proteomics business to genomics giant Illumina, Inc., a transformative deal that nets the company $350 million in upfront cash and creates a war chest of approximately $550 million for future acquisitions. The move marks a dramatic strategic pivot for Standard BioTools, unwinding a major merger from just two years prior and refocusing the company on its core technologies amid significant financial pressures.

In a statement, Standard BioTools confirmed the transaction's closing, which also includes potential near-term earnout payments of up to $75 million and a decade-long 2% royalty stream on certain future product sales. For Illumina, the acquisition is a calculated strike to deepen its capabilities in the burgeoning field of multi-omics. For Standard BioTools, it is both a massive cash infusion and a critical lifeline, providing the capital to reshape its future after years of operational challenges.

“The closing of this transaction marks a major milestone in our strategic transformation. We are lean, focused and extremely well positioned, and emerge today far stronger than we were yesterday,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are now financially resourced to pursue disciplined M&A that accelerates growth and scale like few similarly sized peers in our industry can.”

A Strategic Overhaul and a $550 Million War Chest

The divestiture fundamentally alters Standard BioTools' balance sheet and strategic direction. The influx of cash provides a much-needed foundation for a company that has faced considerable headwinds. Research reveals a challenging financial history, including a 34.1% revenue decline over the past three years and an operating margin of nearly -78%, indicators of deep operational inefficiencies. The company’s Altman Z-Score, a predictor of bankruptcy risk, had recently languished in the “distress zone,” signaling the urgency behind this strategic reset.

The sale effectively reverses the company's own blockbuster merger with SomaLogic, which was completed in January 2024. That deal was originally positioned as a cornerstone of a new strategy to combine leading technologies in genomics, mass cytometry, and proteomics. The rapid reversal suggests the integration proved more challenging than anticipated and that a more drastic course correction was necessary to achieve stability and a path to profitability.

With approximately $550 million in cash and cash equivalents, the company now has the firepower to aggressively pursue acquisitions. Egholm’s emphasis on “disciplined M&A” points toward a strategy of acquiring technologies or companies that can be neatly integrated with its remaining core business, rather than another large-scale, transformative merger. The goal is clear: use the capital to buy growth and accelerate its timeline to positive adjusted EBITDA, which the company projects for 2026.

Illumina Deepens Its Multi-Omics Moat

From Illumina's perspective, the acquisition of SomaLogic’s assets is a significant offensive move. It strengthens the company’s position in the rapidly expanding multi-omics market, where researchers seek to integrate data from genomics, proteomics, and other cellular measurements to gain a more complete picture of health and disease. By bringing SomaLogic’s advanced protein-measurement technology in-house, Illumina can offer more comprehensive and integrated solutions for drug discovery and diagnostics.

The deal builds upon a co-development partnership initiated in late 2021, which aimed to adapt SomaLogic’s SomaScan Proteomics Assay for use on Illumina’s ubiquitous high-throughput next-generation sequencing (NGS) platforms. Acquiring the technology outright allows Illumina to tighten this integration, control the product roadmap, and capture more value from the growing proteomics market, which is projected to reach nearly $94 billion by 2034.

This move also positions Illumina more competitively against rivals like Thermo Fisher Scientific, which recently made its own major proteomics play by acquiring Olink for $3.1 billion. By securing SomaLogic’s powerful platform, Illumina ensures it remains a central player in the race to provide the essential tools for the next generation of biomedical research, reinforcing its commitment to becoming an end-to-end multi-omics solution provider.

A Sharpened Focus on Core Technologies

Stripped of its proteomics arm, the “new” Standard BioTools is a more streamlined entity centered on its two proprietary technology platforms: mass cytometry and microfluidics. These technologies have long been the company’s foundational pillars, serving researchers in oncology, immunology, and immunotherapy.

Its mass cytometry platform, known by the brand name CyTOF, enables highly detailed single-cell analysis, allowing researchers to study dozens of protein markers on individual cells simultaneously. This technology is embodied in systems like the CyTOF XT and the Hyperion XDi spatial imaging system, which provide deep insights into the complex cellular makeup of tissues. The company's microfluidics technology, utilized in systems like the Biomark X9, facilitates high-throughput genomics with reduced costs and greater efficiency.

While technologically sophisticated, these platforms exist in fiercely competitive markets. Standard BioTools now goes head-to-head with specialized and well-funded competitors like 10x Genomics and Cytek Biosciences in the single-cell analysis space. The company’s success will depend on its ability to innovate and effectively market these core products.

By shedding SomaLogic, Standard BioTools has removed a significant source of operational complexity and financial drain. The leadership team is betting that this sharpened focus, combined with operational efficiencies driven by its internal “Standard BioTools Business System,” will finally pave the way to sustained profitability. The stated goal of achieving positive adjusted EBITDA in 2026 now appears more attainable, as the remaining business lines are expected to have a more favorable margin profile.

Navigating a New Path Forward

The transaction provides Standard BioTools with a rare second chance. The $550 million in capital is not just a buffer; it is a mandate for growth. The company’s future now hinges on its ability to execute a savvy M&A strategy, identifying and integrating assets that complement its mass cytometry and microfluidics platforms and drive recurring revenue.

For customers of the former SomaLogic business, Illumina has pledged to ensure continuity of service and support, aiming for a seamless transition. However, as with any major acquisition in the life sciences sector, the integration process will be closely watched for any disruption to services or changes in product strategy.

Ultimately, the sale of SomaLogic is a high-stakes gamble for Standard BioTools. The company has traded a key strategic asset for financial solvency and the opportunity to rebuild. The pressure is now on its leadership to deploy its newfound capital wisely and demonstrate that a leaner, more focused version of the company can achieve the growth and profitability that has long been just out of reach.